ADC Therapeutics SA — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 32 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $23M | ↑+36.4% | — | — | — |
| 2025-09-30 | $16M | ↓-11.0% | $-41M | ↑+6.8% | -188.5% |
| 2025-06-30 | $19M | ↑+8.2% | $-57M | ↓-55.0% | -234.3% |
| 2025-03-31 | $23M | ↑+27.6% | $-39M | ↑+17.2% | -123.6% |
| 2024-12-31 | $17M | ↑+0.7% | — | — | — |
| 2024-09-30 | $18M | ↑+27.4% | $-44M | ↑+5.9% | -192.6% |
| 2024-06-30 | $17M | ↓-9.7% | $-37M | ↑+25.3% | -166.8% |
| 2024-03-31 | $18M | ↓-4.9% | $-47M | ↑+21.5% | -186.2% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$23M
↑+36.4% +$6M YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
ADCT Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyADCT Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics